PET and MR imaging: The odd couple or a match made in heaven?

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 815-824

  Catana, Ciprian ^a   Guimaraes, Alexander R ^a   Rosen, Bruce R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Applications; Cardiology; Multimodality imaging; Neurology; Oncology; PET MR imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BIOTECHNOLOGY; CARDIOLOGY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; EQUIPMENT DESIGN; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; NEUROPSYCHIATRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATIENT MONITORING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOLOGICAL PROCEDURES; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

APPLICATIONS; CARDIOLOGY; MULTIMODALITY IMAGING; NEUROLOGY; ONCOLOGY; PET/MR IMAGING;

ENVIRONMENTAL EXPOSURE; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SYSTEMS INTEGRATION;

EID: 84877146917     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112771     Document Type: Review

References (75)

1. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med. 2004;45(suppl 1):4S-14S.
2. Pichler B, Lorenz E, Mirzoyan R, et al. Performance test of a LSO-APD PET module in a 9.4 Tesla magnet. Paper presented at: 1997 IEEE Nuclear Science Symposium; November 9-15, 1997; Albuquerque, NM.
3. Kolb A, Lorenz E, Judenhofer MS, Renker D, Lankes K, Pichler BJ. Evaluation of Geiger-mode APDs for PET block detector designs. Phys Med Biol. 2010;55:1815-1832.
4. Seong Jong H, In Chan S, Ito M, et al. An investigation into the use of Geigermode solid-state photomultipliers for simultaneous PET and MRI acquisition. IEEE Trans Nucl Sci. 2008;55:882-888.
5. Shao Y, Cherry SR, Farahani K, et al. Simultaneous PET and MR imaging. Phys Med Biol. 1997;42:1965-1970. (Pubitemid 27448997)
6. Schlemmer H-PW, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
7. Catana C, van der Kouwe A, Benner T, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51:1431-1438.
8. Herzog H, Langen KJ, Weirich C, et al. High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin. 2011;50:74-82.
9. Zaidi H, Ojha N, Morich M, et al. Design and performance evaluation of a whole-body Ingenuity TF PET/MRI system. Phys Med Biol. 2011;56:3091-3106.
10. Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914-1922.
11. Sattler B, Jochimsen T, Barthel H, et al. Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. MAGMA. 2013;26:159-171.
12. Martinez-Möller A, Eiber M, Nekolla SG, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012;53:1415-1426.
13. Montandon ML, Zaidi H. Atlas-guided non-uniform attenuation correction in cerebral 3D PET imaging. Neuroimage. 2005;25:278-286. (Pubitemid 40289155)
14. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875-1883.
15. Rota Kops E, Herzog H. Template-based attenuation correction of PET in hybrid MR-PET scanners [abstract]. J Nucl Med. 2008;49(suppl):162P.
16. Reichert ILH, Robson MD, Gatehouse PD, et al. Magnetic resonance imaging of cortical bone with ultrashort TE pulse sequences. Magn Reson Imaging. 2005;23:611-618. (Pubitemid 41033038)
17. Robson MD, Bydder GM. Clinical ultrashort echo time imaging of bone and other connective tissues. NMR Biomed. 2006;19:765-780. (Pubitemid 44811542)
18. Keereman V, Vandenberghe S, De Deene Y, Luypaert R, Broux T. MR-based attenuation correction for PET using an Ultrashort Echo Time (UTE) sequence. Nuclear Science Symposium Conference Record. Piscataway, NJ: IEEE; 2008:4656-4661.
19. Berker Y, Franke J, Salomon A, et al. MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med. 2012;53:796-804.
20. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
21. Schulz V, Torres-Espallardo I, Renisch S, et al. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38:138-152.
22. Catana C, Benner T, van der Kouwe A, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154-161.
23. Chun SY, Reese TG, Ouyang J, et al. MRI-based nonrigid motion correction in simultaneous PET/MRI. J Nucl Med. 2012;53:1284-1291.
24. Dikaios N, Izquierdo-Garcia D, Graves MJ, Mani V, Fayad ZA, Fryer TD. MRI-based motion correction of thoracic PET: initial comparison of acquisition protocols and correction strategies suitable for simultaneous PET/MRI systems. Eur Radiol. 2012;22:439-446.
25. King AP, Buerger C, Tsoumpas C, Marsden PK, Schaeffter T. Thoracic respiratory motion estimation from MRI using a statistical model and a 2-D image navigator. Med Image Anal. 2012;16:252-264.
26. Franzius C. FDG-PET/CT in pediatric solid tumors. Q J Nucl Med Mol Imaging. 2010;54:401-410.
27. McCarville MB. PET-CT imaging in pediatric oncology. Cancer Imaging. 2009;9:35-43.
28. Voss SD. Pediatric oncology and the future of oncological imaging. Pediatr Radiol. 2011;41(suppl 1):S172-S185.
29. 18F fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27:4385-4391.
30. Hawkins DS, Conrad EU, Butrynski JE, Schuetze SM, Eary JF. F-18-fluoro-deoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115:3519-3525.
31. Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT. Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med. 2009;50:1570-1577.
32. Robbins E. Radiation risks from imaging studies in children with cancer. Pediatr Blood Cancer. 2008;51:453-457.
33. Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316-331. (Pubitemid 47247399)
34. Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50:1483-1491.
35. Fruehwald-Pallamar J, Czerny C, Mayerhoefer ME, et al. Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. Eur J Nucl Med Mol Imaging. 2011;38:1009-1019.
36. 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009;19:634-642.
37. 11C-acetate PET/CT. Eur J Radiol. 2012;81:2966-2972.
38. Park H, Wood D, Hussain H, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53:546-551.
39. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12:181-191.
40. Moy L, Ponzo F, Noz ME, et al. Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med. 2007;48:528-537. (Pubitemid 47571406)
41. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674-684.
42. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31:19-31.
43. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:303-311.
44. Kwee TC, Nievelstein RAJ. Is MRI less accurate than FDG-PET/CT in diagnosing bone marrow involvement in lymphoma? Eur J Radiol. 2011;80:565-566.
45. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res. 2007;13(suppl):770S-776S.
46. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777. (Pubitemid 46622044)
47. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-3054. (Pubitemid 47218051)
48. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. (Pubitemid 46075199)
49. Guimaraes AR, Ross R, Figuereido JL, Waterman P, Weissleder R. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. Mol Imaging Biol. 2011;13:314-320.
50. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imaging. 2009;36(suppl):S121-S130.
51. Zhang WY, Ebert AD, Narula J, Wu JC. Imaging cardiac stem cell therapy: translations to human clinical studies. J Cardiovasc Transl Res. 2011;4:514-522.
52. Jarrett BR, Gustafsson B, Kukis DL, Louie AY. Synthesis of Cu-64-labeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem. 2008;19:1496-1504. (Pubitemid 352032352)
53. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD): conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-1379.
54. Uppal R, Catana C, Ay I, et al. Simultaneous MR-PET imaging of thrombus with a fibrin-targeted dual MR-PET probe: a feasibility study. Radiology. 2011;258:812-820.
55. WHO. The global burden of disease: 2004 update. http://www.who.int/ healthinfo/global-burden-disease/GBD-report-2004update-part4.pdf.
56. Rosen BR, Savoy RL. fMRI at 20: has it changed the world? Neuroimage. 2012;62:1316-1324.
57. Pina-Camacho L, Villero S, Fraguas D, et al. Autism spectrum disorder: does neuroimaging support the DSM-5 proposal for a symptom dyad? A systematic review of functional magnetic resonance imaging and diffusion tensor imaging studies. J Autism Dev Disord. 2012;42:1326-1341.
58. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64:492-498.
59. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709-7717. (Pubitemid 41208641)
60. Jack CR, Lowe VJ, Senjem ML, et al. C-II PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain. 2008;131:665-680. (Pubitemid 351294719)
61. Villain N, Desgranges B, Viader F, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci. 2008;28:6174-6181.
62. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010;12:27-43.
63. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009;119:717-725.
64. Curvo-Semedo L, Diniz M, Miguéis J, et al. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging. 2006;24:123-131.
65. Memarsadeghi M, Riedl CC, Kaneider A, et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology. 2006;241:367-377. (Pubitemid 44632881)
66. Tokuhara T, Tanigawa N, Matsuki M, et al. Evaluation of lymph node metastases in gastric cancer using magnetic resonance imaging with ultrasmall superparamagnetic iron oxide (USPIO): diagnostic performance in post-contrast images using new diagnostic criteria. Gastric Cancer. 2008;11:194-200.
67. Barentsz JO, Futterer JJ, Takahashi S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol. 2007;63:369-372. (Pubitemid 47321043)
68. Lambregts DMJ, Beets GL, Maas M, et al. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg. 2011;253:539-545.
69. Nakamatsu S, Matsusue E, Miyoshi H, Kakite S, Kaminou T, Ogawa T. Correlation of apparent diffusion coefficients measured by diffusion-weighted MR imaging and standardized uptake values from FDG PET/CT in metastatic neck lymph nodes of head and neck squamous cell carcinomas. Clin Imaging. 2012;36:90-97.
70. Ohno Y, Koyama H, Yoshikawa T, et al. N-stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology. 2011;261:605-615.
71. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41:265-282.
72. Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathological presentation of varying F-18-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med. 2008;22:83-86. (Pubitemid 351207655)
73. Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer. 2010;47:120-125.
74. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol. 2000;18:321-325. (Pubitemid 30159486)
75. Frullano L, Catana C, Benner T, Sherry AD, Caravan P. Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl. 2010;49:2382-2384.